Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Mallinckrodt PLC    MNK   IE00BBGT3753

MALLINCKRODT PLC (MNK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Mallinckrodt : To Present At Deutsche Bank's 43rd Annual Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2018 | 11:46am CEST

STAINES-UPON-THAMES - Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, May 9, 2018, at Deutsche Bank's 43rd Annual Healthcare Conference at the Intercontinental Hotel Boston, 510 Atlantic Ave., in Boston.

Mark Trudeau, President and Chief Executive Officer, and Dr. Steven Romano, Executive Vice President and Chief Scientific Officer, will represent the company in a fireside chat at 12:50 p.m. Eastern.

ABOUT MALLINCKRODT

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contact:

Daniel J. Speciale

Tel: 314-654-3638

Email: daniel.speciale@mnk.com

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
DEUTSCHE BANK 1.60% 10.536 Delayed Quote.-33.63%
MALLINCKRODT PLC -0.40% 29.64 Delayed Quote.31.38%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MALLINCKRODT PLC
09/19MALLINCKRODT : Announces Donation of Two Transport Vehicles to Coolmine Therapeu..
AQ
09/19MALLINCKRODT : Announces Donation of Two Transport Vehicles to Coolmine Therapeu..
AQ
09/17MALLINCKRODT : Announces Donation of Two Transport Vehicles to Coolmine Therapeu..
PU
09/06MALLINCKRODT : to Present at Cantor Global Healthcare Conference
AQ
09/04MALLINCKRODT : To Present At Cantor Global Healthcare Conference
PR
08/30MALLINCKRODT : And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of..
AQ
08/23MALLINCKRODT : And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of..
PR
08/22MALLINCKRODT : As anticipated, FDA rebuffs Mallinckrodt's stannsoporfin
AQ
08/22MALLINCKRODT : Confirms Receipt of Stannsoporfin Complete Response Letter
PR
08/21TODAY'S RESEARCH REPORTS ON TRENDING : Mallinckrodt and Perrigo Company
AC
More news
News from SeekingAlpha
09/18Senate passes opioid crisis bill 
09/14STOCK EXCHANGE : Hindenburg Omen Flashing Red, Is It Reliable? 
09/13ABUSE-DETERRENT OPIOIDS : A Business Answer To The Opioid Abuse Crisis 
09/12Nostrum Labs hikes price of mature antibiotic 400% 
09/11Premarket analyst action - healthcare 
Financials ($)
Sales 2018 2 485 M
EBIT 2018 992 M
Net income 2018 192 M
Debt 2018 5 597 M
Yield 2018 -
P/E ratio 2018 24,39
P/E ratio 2019 10,46
EV / Sales 2018 3,25x
EV / Sales 2019 2,78x
Capitalization 2 476 M
Chart MALLINCKRODT PLC
Duration : Period :
Mallinckrodt PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MALLINCKRODT PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 31,1 $
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Mark C. Trudeau President, Chief Executive Officer & Director
Angus C. Russell Chairman
Frank Scholz EVP-Global Operations & Digital Innovation Officer
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Steven Romano Chief Scientific Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
MALLINCKRODT PLC31.38%2 476
ABBVIE-4.60%140 343
MERCK KGAA-2.89%13 233
KYOWA HAKKO KIRIN CO LTD-6.21%10 668
JAZZ PHARMACEUTICALS PLC21.63%9 929
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD53.61%8 308